HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

Design Therapeutics, Inc.

Contributing Author

Recent Articles by Design Therapeutics, Inc.

Jun-04
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 DSGN GlobeNewswire
May-28
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference DSGN GlobeNewswire
May-13
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference DSGN GlobeNewswire
May-07
Design Therapeutics Highlights Momentum Across Lead GeneTAC Programs and Reports First Quarter 2025 Financial Results DSGN GlobeNewswire
May-01
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy DSGN GlobeNewswire
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite